Statins and the nursing home

Journal of the American Medical Directors Association

Volumn 14, Issue 12, 2013, Pages 853-854

  Morley, John E ^a   Mahon, Gerald ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATINE KINASE; CYTOKINE; FRUCTOSE BISPHOSPHATE ALDOLASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COGNITION; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DEMENTIA; EDITORIAL; ENZYME BLOOD LEVEL; GERIATRIC PATIENT; HEART INFARCTION; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; MYOSITIS; NURSING HOME; NURSING HOME PATIENT; PHYSICIAN; POLYPHARMACY; RISK REDUCTION; SARCOPENIA; VITAMIN BLOOD LEVEL; WEIGHT REDUCTION;

CHOLESTEROL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGEVITY; MALE;

EID: 84896945910     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.09.016     Document Type: Editorial

References (55)

1. Jacobs J.M., Cohen A., Ein-Mor E., Stessman J. Cholesterol, statins, and longevity from age 70 to 90 years. JAm Med Dir Assoc 2013, 14:883-888.
2. Morley J.E. The cholesterol conundrum. JAGS 2011, 59:1955-1956.
3. Argiles J.M., Anker S.D., Evans W.J., et al. Consensus on cachexia definitions. JAm Med Dir Assoc 2010, 11:229-230.
4. Rolland Y., Perrin A., Gardette V., et al. Screening older people at risk of malnutrition or malnourished using the Simplified Nutritional Appetite Questionnaire (SNAQ): A comparison with the Mini-Nutritional Assessment (MNA) tool. JAm Med Dir Assoc 2012, 13:31-34.
5. Bell C.L., Tamura B.K., Masaki K.H., Amella E.J. Prevalence and measures of nutritional compromise among nursing home patients: Weight loss, low body mass index, malnutrition, and feeding dependency, a systematic review of the literature. JAm Med Dir Assoc 2013, 14:94-100.
6. Farkas J., von Haehling S., Kalantar-Zadeh K., et al. Cachexia as a major public health problem: Frequent, costly, and deadly. JCachexia Sarcopenia Muscle 2013, 4:173-178.
7. Morley J.E. Undernutrition: A major problem in nursing homes. JAm Med Dir Assoc 2011, 12:243-246.
8. Tamura B.K., Bell C.L., Masaki K.H., Amella E.J. Factors associated with weight loss, low BMI, and malnutrition among nursing home patients: A systematic review of the literature. JAm Med Dir Assoc 2013, 14:649-655.
9. Soenen S., Chapman I.M. Body weight, anorexia, and under nutrition in older people. JAm Med Dir Assoc 2013, 14:642-648.
10. Morley J.E. Weight loss in older persons: New therapeutic approaches. Curr Pharm Des 2007, 13:3637-3647.
11. Morley J.E., Vellas B., van Kan G.A., et al. Frailty consensus: A call to action. JAm Med Dir Assoc 2013, 14:392-397.
12. Le Reste J.Y., Nabbe P., Manceau B., et al. The European General Practice Research Network presents a comprehensive definition of multimorbidity in family medicine and long term care, following a systematic review of relevant literature. JAm Med Dir Assoc 2013, 14:319-325.
13. Morley J.E. Frailty, falls, and fractures. JAm Med Dir Assoc 2013, 14:149-151.
14. Hoogendijk E.O., van Hout H.P. Investigating measurement properties of the Groningen Frailty Indicator: A more systematic approach is needed. JAm Med Dir Assoc 2012, 13:757.
15. Peters L.L., Boter H., Buskens E., Slaets J.P. Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people. JAm Med Dir Assoc 2012, 13:546-551.
16. Ranieri P., Rozzini R., Franzoni S., et al. Serum cholesterol levels as a measure of frailty in elderly patients. Exp Aging Res 1998, 24:169-179.
17. Kalantar-Zadeh K., Horwich T.B., Oreopoulos A., et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007, 10:433-442.
18. Allen Maycock C.A., Muhlestein J.B., Horne B.D., et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. JAm Coll Cardiol 2002, 40:1777-1785.
19. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207.
20. Goldstein M.R., Mascitelli L., Pezzetta F. Statin therapy, muscle function and vitamin D. QJ Med 2009, 890-891.
21. Scott D., Blizzard L., Fell J., Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJ Med 2009, 102:625-633.
22. Bhardwaj S., Selvarajah S., Schneider E.B. Muscular effects of statins in the elderly female: A review. Clin Intervent Aging 2013, 8:47-59.
23. Saliba D., Jones M., Streim J., et al. Overview of significant changes in the Minimum Data Set for nursing homes version 3.0. JAm Med Dir Assoc 2012, 13:595-601.
24. Whitney J., Close J.C., Jackson S.H., Lord S.R. Understanding risk of falls in people with cognitive impairment living in residential care. JAm Med Dir Assoc 2012, 13:535-540.
25. Morley J.E., Rolland Y., Tolson D., Vellas B. Increasing awareness of the factors producing falls: The mini falls assessment. JAm Med Dir Assoc 2012, 13:87-90.
26. Morley J.E. Falls and fractures. JAm Med Dir Assoc 2007, 8:276-278.
27. Scott D., Blizzard L., Fell J., Jones G. The epidemiology of sarcopenia in community living older adults: What role does lifestyle play?. JCachexia Sarcopenia Muscle 2011, 2:125-134.
28. Cesari M., Vellas B. Sarcopenia: A novel clinical condition or still a matter for research?. JAm Med Dir Assoc 2012, 13:766-767.
29. Landi F., Liperoti R., Fusco D., et al. Sarcopenia and mortality among older nursing home residents. JAm Med Dir Assoc 2012, 13:121-126.
30. Morley J.E., Abbatecola A.M., Argiles J.M., et al. Sarcopenia with limited mobility: An international consensus. JAm Med Dir Assoc 2011, 12:403-409.
31. Fielding R.A., Vellas B., Evans W.J., et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International Working Group on Sarcopenia. JAm Med Dir Assoc 2011, 12:249-256.
32. Ahmed W., Khan N., Glueck C.J., et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009, 153:11-16.
33. Janssen H.C., Emmelot-Vonk M.H., Verhaar H.J., van der Schouw Y.T. Vitamin D and muscle function: Is there a threshold in the relation?. JAm Med Dir Assoc 2013, 14:627.e13-627.e18.
34. Faulhaber G.A., Schulz L.F., Furlanetto T.W. Vitamin D status and ICU outcomes: Potential confounders. JAm Med Dir Assoc 2011, 12:e1-e2.
35. Song Y., Nie H., Xu Y., et al. Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies. Geriatr Gerontol Int 2013, [Epub ahead of print]. 10.1111/ggi.12044.
36. Rojas-Fernandez C.H., Cameron J.C. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012, 46:549-557.
37. Wagstaff L.R., Mitton M.W., Arvik B.M., Doraiswamy P.M. Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880.
38. Steenland K., Zhao L., Goldstein F.C., Levey A.I. Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. JAm Geriatr Soc 2013, 61:1449-1455.
39. Morley J.E., Banks W.A. Lipids and cognition. JAlzheimers Dis 2010, 20:737-747.
40. Padala K.P., Padala P.R., McNeilly D.P., et al. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: A prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012, 10:296-302.
41. Onder G., Liperoti R., Foebel A., et al. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: Results from the SHELTER study. JAm Med Dir Assoc 2013, 14:450.e7-450.e12.
42. Little M.O., Morley A. Reducing polypharmacy: Evidence from a simple quality improvement initiative. JAm Med Dir Assoc 2013, 14:152-156.
43. Kojima G., Bell C., Tamura B., et al. Reducing cost by reducing polypharmacy: The polypharmacy outcomes project. JAm Med Dir Assoc 2012, 13:818.e11-818.e15.
44. Beier M.T. Updated 2012 Beers Criteria: What's noteworthy and cautionary?. JAm Med Dir Assoc 2012, 13:768-769.
45. Bronskill S.E., Gill S.S., Paterson J.M., et al. Exploring variation in rates of polypharmacy across long term care homes. JAm Med Dir Assoc 2012, 13:309.e15-309.e21.
46. Tamura B.K., Bell C.L., Lubimir K., et al. Physician intervention for medication reduction in a nursing home: The polypharmacy outcomes project. JAm Med Dir Assoc 2011, 12:326-330.
47. Fitzgerald S.P., Bean N.G. An analysis of the interactions between individual comorbidities and their treatments-Implications for guidelines and polypharmacy. JAm Med Dir Assoc 2010, 11:475-484.
48. Gokce Kutsal Y., Barak A., Atalay A., et al. Polypharmacy in the elderly: A multicenter study. JAm Med Dir Assoc 2009, 10:486-490.
49. Stripoli G.F.M., Craig J.C. Sunset for statins after AURORA?. NEngl J Med 2009, 360:1455-1456.
50. Petersen L.K., Christensen K., Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing 2010, 39:676-680.
51. Yan Y.L., Qiu B., Hu L.J., et al. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: A systematic review and meta-analysis. Eur J Clin Pharmacol 2013, [Epub ahead of print].
52. Tolson D., Rolland Y., Andrieu S., et al. International Association of Gerontology and Geriatrics: A global agenda for clinical research and quality of care in nursing homes. JAm Med Dir Assoc 2011, 12:184-189.
53. Parikh S., Shrank W.H., Mogun H., Choudhry N.K. Statin utilization in nursing home patients after cardiac hospitalization. JGen Intern Med 2010, 25:1293-1299.
54. Garcia-Gollarte F., Baleriola-Julvez J., Ferrero-Lopez I., Cruz-Jentoft A.J. Inappropriate drug prescription at nursing home admission. JAm Med Dir Assoc 2012, 13:83.e9-83.e15.
55. Joseph J., Koka M., Aronow W.S. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home. JAm Med Dir Assoc 2008, 9:124-127.